Pain Therapeutics Reports 2011 Financial Results

Feb 09, 2012

— Balance Sheet Remains Strong —

— Disciplined Spending Expected in 2012 —

AUSTIN, Texas, Feb. 9, 2012 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) today reported financial results for the full year ended December 31, 2011. Net loss was $2.6 million in 2011, or $0.06 per share, compared to a net loss of $12.0 million in 2010, or $0.28 per share.

Cash and equivalents stood at $98.1 million at December 31, 2011. Net cash usage for the first half of 2012 is expected to be under $5.0 million. The Company has no debt.

"2012 may be an important year for Pain Therapeutics," said Remi Barbier, President & CEO. "We have a strong balance sheet, a history of disciplined spending and a late-stage drug asset under development by Pfizer. We also have a highly focused research and development strategy and significant management ownership of the Company. With these strengths, I think we have the potential to build a major business in biotechnology."

2011 Financial Detail

  • Collaboration revenue of $0.6 million reflects reimbursement of our development expenses under our strategic alliance with Pfizer.
  • Research and development expenses decreased to $8.3 million in 2011 from $15.7 million in 2010. Research and development expenses included $2.7 million in non-cash stock related compensation costs in 2011 and $10.3 million in 2010. This includes $7.4 million related to a special, one-time nondividend distribution in December 2010. 
  • General and administrative expenses decreased to $6.7 million in 2011 from $14.8 million in 2010. General and administrative expenses included $2.8 million in non-cash stock related compensation costs in 2011 and $9.9 million in 2010. This includes $7.4 million related to a special, one-time nondividend distribution in December 2010.


Our lead drug is called REMOXY®. It is an investigational extended-release oral formulation of oxycodone for the relief of moderate to severe pain requiring continuous, around-the-clock opioid treatment.  We developed REMOXY to discourage common methods of drug tampering.

On June 24, 2011, we and partner Pfizer, Inc. (NYSE:PFE) announced that a Complete Response Letter was received from the U.S. Food and Drug Administration (FDA) on the resubmission to the new drug application (NDA) for REMOXY (oxycodone) Extended-Release Capsules CII. Pfizer is working to evaluate the issues described in the Complete Response Letter and plans to have further discussions with the FDA around them. Pfizer has full control of the development and funding of REMOXY.

In 2005, we entered into a strategic alliance with King Pharmaceuticals, Inc. (King) to develop and commercialize REMOXY. We filed the initial NDA for REMOXY in June 2008 and received a Complete Response Letter in December 2008. King assumed full control of the development of REMOXY in March 2009; filed a resubmission to the REMOXY NDA in December 2010; and received a Complete Response Letter for such resubmission in June 2011. Pfizer obtained rights to REMOXY upon the close of its acquisition of King in February 2011. 

  • Pfizer is our exclusive, worldwide commercial partner for REMOXY and three other abuse-resistant prescription pain medications (except in Australia/New Zealand).
  • Upon the commercial launch of REMOXY, we will receive from Pfizer a royalty of 20% of net sales in the United States, except as to the first $1.0 billion in cumulative net sales, which royalty is set at 15%. Outside the United States, the royalty rate is 10%.
  • In addition, we will receive from Pfizer a supplemental royalty fee payment of 6.0% to 11.5% of net sales, depending on the range of total dollar sales in each year. This supplemental payment is equal to the full amount of our financial obligations to Durect Corporation (Nasdaq:DRRX), our exclusive supplier of certain excipients in REMOXY.
  • To date, we have received total cash payments of $185.0 million in program fees and milestone payments under the strategic alliance in connection with the development of REMOXY and three other abuse-resistant drug candidates.
  • Under the terms of our strategic alliance with Pfizer, we are eligible to receive up to an additional $120.0 million in clinical/regulatory milestone payments, including a $15.0 million payment upon FDA approval of REMOXY.
  • Our development expenses for REMOXY and three other abuse-resistant pain medications that are in various stages of development, including hydrocodone, hydromorphone and oxymorphone, are reimbursed by Pfizer.
  • Pain Therapeutics retains commercial rights to REMOXY and three other abuse-resistant drug candidates in Australia/New Zealand. We have not yet announced a market entry strategy for these territories.

About Pain Therapeutics, Inc.

Pain Therapeutics, Inc. is a biopharmaceutical company that develops novel drugs. The FDA has not approved any of our drug candidates for commercial sale.  For more information, please visit

Note Regarding Forward-Looking Statements: This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Pain Therapeutics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, any statements relating to our projected cash requirements for the first half of 2012, our potential to build a major business in biotechnology; potential future milestone payments and royalties based on revenue from REMOXY, the potential development of other abuse resistant drug candidates, and funding obligations of Pfizer. Such statements are based on management's current expectations, but actual results may differ materially due to various factors. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in obtaining regulatory approval of REMOXY and in development, testing and pursuit of regulatory approval of our other drug candidates, unexpected adverse side effects or inadequate therapeutic efficacy of our drug candidates, difficulties or delays in commercialization efforts with respect to our products, if any are approved for marketing, or failure of such products to gain market acceptance, the uncertainty of patent protection for our intellectual property or trade secrets, unanticipated additional research and development and other costs, the timing and receipt of funds from Pfizer, potential diversion of resources from the pursuit of development and commercialization of drug candidates subject to our strategic alliance with Pfizer as a result of the acquisition of King by Pfizer, and the potential for abuse resistant pain medications or other competing products or therapies to be developed by competitors and potential competitors or others. For further information regarding these and other risks related to the Company's business, investors should consult the Company's filings with the Securities and Exchange Commission.

- Financial Tables Follow -

(in thousands, except per share amounts)
  Three Months Ended December 31, Year Ended December 31,
  2011 2010 2011 2010(1)
 Program fee revenue   $ 2,724  $ 2,724  $ 10,897  $ 10,496
 Collaboration revenue   23  285  587  1,313
 Milestone revenue   --   5,000  --   5,000
 Total revenue   2,747  8,009  11,484  16,809
 Operating expenses         
 Research and development   1,711  8,010  8,300  15,746
 General and administrative   1,620  9,510  6,698  14,766
 Total operating expenses   3,331  17,520  14,998  30,512
 Operating loss   (584)  (9,511)  (3,514)  (13,703)
 Interest income   193  340  901  1,680
 Net loss   $ (391)  $ (9,171)  $ (2,613)  $ (12,023)
 Net loss per share - basic and diluted   $ (0.01)  $ (0.21)  $ (0.06)  $ (0.28)
 Weighted-average shares used in computing net loss per share - basic and diluted   44,671  42,797  44,160  42,644
      December 31,
      2011 2010(1)
 Current assets         
 Cash, cash equivalents and marketable securities     $ 98,131  $ 91,226
 Receivables       --   7,114
 Other current assets       358  144
 Total current assets       98,489  98,484
 Non-current assets         
 Property and equipment, net       122  285
 Other assets       352  426
 Total assets       $ 98,963  $ 99,195
 Liabilities and stockholders' equity         
 Current liabilities         
 Accounts payable and accrued development expenses     $ 1,378  $ 1,365
 Deferred program fee revenue - current portion     10,897  10,897
 Other accrued liabilities       997  1,809
 Total current liabilities       13,272  14,071
 Non-current liabilities         
 Deferred program fee revenue - non-current portion     40,863  51,760
 Other liabilities       435  431
 Total liabilities       54,570  66,262
 Stockholders' equity         
 Common stock       45  43
 Additional paid-in-capital       176,425  161,957
 Accumulated other comprehensive income       128  525
 Accumulated deficit       (132,205)  (129,592)
 Total stockholders' equity       44,393  32,933
 Total liabilities and stockholders' equity       $ 98,963  $ 99,195
(1) Derived from the Company's annual financial statements as of December 31, 2010, included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission.
CONTACT: Peter S. Roddy

         Vice President and Chief Financial Officer

         Pain Therapeutics, Inc.

         (512) 501-2450